Difference between revisions of "Part:BBa K4429013"
Line 3: | Line 3: | ||
<partinfo>BBa_K4429013 short</partinfo> | <partinfo>BBa_K4429013 short</partinfo> | ||
− | - | + | NeoFvs are engineered antibody fragments. An scFv is defined as the variable domains of a full length antibody connected via a flexible linker. A NeoFv is a name given by iGEM 2022 team IISER-Pune2_India to scFvs with a small peptide extension that binds to the human neonatal Fc receptor (or FcRn receptor). Such scFvs with an FcRn binding peptide have recently been described in literature [1] with potential to overcome the size problem of scFvs, and extend their half life of circulation in the human body. |
+ | |||
+ | NeoFv513 VH-VL-LinY12H is one such NeoFv derived from the Ab513 antibody targeting the envelope protein domain III epitope of the Dengue virus. A NeoFv derived from Ab513 can ideally be a therapy for Dengue fever. | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
Line 17: | Line 19: | ||
<partinfo>BBa_K4429013 parameters</partinfo> | <partinfo>BBa_K4429013 parameters</partinfo> | ||
<!-- --> | <!-- --> | ||
+ | |||
+ | |||
+ | ===References=== | ||
+ | *1]Short FcRn-Binding Peptides Enable Salvage and Transcytosis of scFv Antibody Fragments | ||
+ | Vince W. Kelly and Shannon J. Sirk | ||
+ | ACS Chemical Biology 2022 17 (2), 404-413 | ||
+ | DOI: 10.1021/acschembio.1c00862 |
Latest revision as of 03:36, 14 October 2022
NeoFv513 VH-VL-LinY12H
NeoFvs are engineered antibody fragments. An scFv is defined as the variable domains of a full length antibody connected via a flexible linker. A NeoFv is a name given by iGEM 2022 team IISER-Pune2_India to scFvs with a small peptide extension that binds to the human neonatal Fc receptor (or FcRn receptor). Such scFvs with an FcRn binding peptide have recently been described in literature [1] with potential to overcome the size problem of scFvs, and extend their half life of circulation in the human body.
NeoFv513 VH-VL-LinY12H is one such NeoFv derived from the Ab513 antibody targeting the envelope protein domain III epitope of the Dengue virus. A NeoFv derived from Ab513 can ideally be a therapy for Dengue fever.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
References
- 1]Short FcRn-Binding Peptides Enable Salvage and Transcytosis of scFv Antibody Fragments
Vince W. Kelly and Shannon J. Sirk ACS Chemical Biology 2022 17 (2), 404-413 DOI: 10.1021/acschembio.1c00862